Suboptimal immunity of hepatitis B vaccination and seroprotection among healthcare professionals in a tertiary hospital in Ghana Authors: Benedict Boateng Antuamwine, Obed Moafagma Kuchando, Walida Alhassan, Maxwell Akonde Published: 2025 ABSTRACT Healthcare workers (HCW) constitute a high-risk group to hepatitis B virus (HBV) infection, which can be curtailed by vaccination. Despite two decades of HBV vaccinations in Ghana, there is limited data on the sero-protection (anti-HBs titer ≥ 10 mIU/ml) rate among vaccinated individuals. To determine the extent of anti-HBs sero-protection among HCW, we conducted a cross-sectional study involving 150 HBV-vaccinated HCW at the Tamale Teaching Hospital, who were recruited between March and September 2019. Demographics and vaccination history were collected through questionnaires. Blood samples were tested for HBsAg and anti-HBs antibodies using test kits and ELISA immunoassay respectively. Results showed that 62% of HBV-vaccinated HCW had sufficient protection, with a mean titer of 338.6 ± 387.6 mIU/ml. However, 38% had antibody titers below the protective threshold (< 10 mIU/ml). Notably, one individual with suboptimal immunity tested positive for HBsAg. Age, but not gender and body mass index, influenced the antibody levels. Our findings suggest that a substantial proportion of HBV-vaccinated HCW in Ghana may lack adequate seroprotection and may be prone to HBV infection. The study highlights the importance of considering routine evaluation of anti-HBs antibody titers among HCW to better inform occupational health policies.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-27938-2. Introduction Hepatitis B virus (HBV) infection continues to impose a substantial global health burden despite the availability of effective vaccines for more than four decades. First identified in the mid-1960s, HBV has since remained a major public health challenge in both high- and low-resource settings. Current estimates suggest that nearly one in three individuals worldwide has been exposed to HBV at some point in their lives, with approximately 1.2 million new infections occurring annually1,2. In Sub-Saharan Africa, HBV infection is endemic, where the seroprevalence of hepatitis B surface antigen (HBsAg) is estimated at 6.7%1. The situation in Ghana, however, is particularly alarming, with HBsAg prevalence ranging from 9.1% to 12.3%, and over 200,000 new infections reported annually1,3,4. HBV-related morbidity and mortality continue to exert a considerable toll on public health in Ghana, accounting for an estimated 3,120 deaths each year1,5. Although recent studies suggest a downward trend in HBV prevalence, particularly among pregnant women, with rates of 6.0%6, 7.5%7 and 7.7%8, compared with earlier reports over a decade ago that documented rates of 11–17% in similar populations4,9,10, the burden remains considerably high. In Ghana, healthcare workers, who face increased occupational risk, considering their frequent exposure to blood, body fluids and accidental sharps11 are particularly vulnerable, with HBV prevalence estimated at nearly 6%12. About 63% of Ghanaian healthcare workers report frequent contact with blood or body fluids suspected to be contaminated with HBV, while 8.2% show serological evidence of lifetime HBV exposure based on hepatitis B core antibody (HBc) positivity13. These exposure rates exceed global averages and are significantly higher in resource-constrained settings. This persistent burden reflects critical gaps in vaccination coverage, post-vaccination serological monitoring, and occupational health policies designed to protect this high-risk population. A vaccination schedule of 0, 1 and 6 months in adults, recommended by the WHO is adopted by the Ghana’s Ministry of Health in its National Guidelines for prevention, care and treatment of viral hepatitis14,15. However, HBV vaccination is not mandatory for healthcare workers, and recent studies have highlighted the need for policies that make vaccination compulsory to reduce occupational risk and nosocomial transmission16. Although hepatitis B vaccination programs have significantly reduced infection rates, achieving the global eradication target by 2030 remains unlikely17. A notable concern is vaccine non-response, where 5–10% of individuals fail to develop protective antibody levels (≥ 10 mIU/ml) despite completing the full vaccine dose18–20. This suboptimal immunity leaves a fraction of vaccinated populations, including healthcare workers, still vulnerable to the infection. Recent studies have documented breakthrough infection rates of 1%20 and 2.4%21 among vaccinated healthcare workers in Ghana. Following completion of the hepatitis B vaccination, healthcare workers are recommended to be tested for hepatitis B surface antibody (anti-HBs) 1–2 months after vaccination to confirm protective immunity22,23. Testing beyond this window may underestimate the true response due to natural antibody decline24. While highly effective vaccines are in use, the absence of routine antibody titer monitoring, commonly practiced in many developed countries25, leaves a proportion of healthcare professionals inadequately protected. Such monitoring is valuable for identifying non-responders, who can then be offered higher doses or additional booster vaccinations to optimize their immune response. In low- and middle-income countries, including Ghana, this practice is largely absent, leaving vaccinated individuals without confirmation of protection. While this gap may be less critical for low-risk populations, it is particularly concerning for healthcare workers, for whom post-vaccination immunity checks are essential. Ensuring healthcare professionals know their post-vaccination antibody status will minimize HBV transmission, guide the need for additional doses, and protect non-responders from high-risk exposures. Against this background, the aim of the study was to assess the seroprotection status of healthcare professionals in a tertiary hospital in Ghana following hepatitis B vaccination. Specifically, we evaluated anti-HBs antibody titers to determine the proportion of individuals who achieved adequate immunity, identify potential non-responders and highlight gaps in existing occupational health protocols. These findings are expected to inform targeted interventions aimed at strengthening hepatitis B prevention and control strategies among healthcare workers in high-burden, resource-limited settings. Materials and methods Study design and area This was a cross-sectional study that was conducted at the Tamale Teaching Hospital, Ghana, among healthcare workers who had been vaccinated against HBV. The Tamale Teaching Hospital is a public referral hospital in Tamale, the capital city of the Northern Region, extending its services to neighboring regions within the northern part of Ghana. With an estimated staff capacity of 1,800, of which 1,100 are medical and allied health staff and the rest are support staff, the hospital also serves as the main teaching facility for the School of Medicine and Allied Health Sciences of the University for Development Studies. The study site was specifically selected based on its high volume of clinical procedures and patient turnover, factors that increase the risk of occupational exposure to HBV among HCW. Study sample The study consisted of HCW at the Tamale Teaching Hospital who had received at least one dose of the hepatitis B vaccine. A total of one hundred and fifty (150) vaccinated healthcare workers were randomly recruited from this facility between March and September 2018. The sample size was determined using the formula: n =[Z2 x p(1-p)]/e2, where n is the required sample size, Z is the standard deviation at 95% confidence interval (1.96), p is the estimated prevalence of HBV infection (11.1%) from previous studies4 and e is the margin of error set at 5%. The participants were HCW employed at the Tamale Teaching Hospital for at least six months who self-reported having previously received the HBV vaccine. Inclusion criteria for participation in the study were confirmation of employment status as a healthcare using a staff ID, and verification of having received at least one dose of the hepatitis B vaccine. Healthcare workers with chronic ailments such as diabetes, hypertension, chronic kidney disease among others were excluded from the study. Ethical clearance was granted by the Quality Assurance and Ethical Review Committee of the University for Development Studies, Tamale, with the institutional review number SAHS-QAERC-MLS/600-09/1416/20,172,018. We confirm that the research was performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all subjects involved in the study. Participants were allowed to withdraw at any stage of the study without providing reasons. Questionnaire data A pre-designed questionnaire was administered to collect information on sociodemographic characteristics (age, sex, profession, and marital status), clinical factors (blood pressure and body mass index), and vaccination history including the number of hepatitis B vaccine doses received and the interval since the last dose. The questionnaire was developed based on a review of validated instruments used in previous HBV vaccination and seroprotection studies18. Items were adapted to align with the objective of the current study and tailored to the local Ghanaian healthcare context. The sample questionnaire is provided as supplementary information. Laboratory procedures Sample collection From each participant, 4 ml of venous blood sample was collected into a gel separator tube and allowed to clot. The clotted sample was then centrifuged at 4000 rpm for 5 minutes, after which 2 ml of serum was aliquoted into cryovials and stored at −20 °C untill analysis. The remaining serum in the gel separator tubes was used to test for hepatitis B surface antigen. Detection of HBsAg in human serum Detection of HBs in serum was performed employing the rapid detection HBsAg test kit, Wondfo® (Guangzhou Wondfo Biotech Co., Ltd., China). 100 µl of serum was added to the sample well of the test kit and incubated at room temperature for 15 min, after which the results were interpreted as reactive or non-reactive. Reactive samples displayed two rose-pink bands on the test kit: one on the test region and the other on the control region, whereas non-reactive samples showed only a single band in the control region. ELISA for anti-HBs titer estimation The enzyme-linked immunosorbent assay (ELISA) was employed to estimate anti-HBs titers in the sera of vaccinated and non-vaccinated subjects, following the manufacturer’s instructions. Briefly, wells of 96-well microtiter plates were each coated with 100 µl of the hepatitis B recombinant antigen at a concentration of 0.5 µg/ml and incubated overnight at 4oC. The plates were then washed 3 times with 200 µl/well of wash buffer (1x PBS with 0.1% Tween-20) and blotted on paper towels. Blocking was performed by adding 200 µl/well blocking buffer (1x PBS with 0.1% Tween-20 and 5% skimmed milk) and incubating for 1 hour at room temperature. Plates were washed again 3 times with wash buffer and blotted. Two-fold serial dilutions of anti-HBs standards were prepared in dilution buffer (1x PBS with 0.1% Tween-20 and 2.5% skimmed milk). After several titrations, a 1:10 dilution of test samples was determined to be optimal for titer estimation. 100 µl of test samples or standards were added in triplicate to the wells and incubated for 2 hrs at room temperature. The plates were subsequently washed and blotted as described earlier. A secondary antibody, goat anti-human IgG conjugated to horse-radish peroxidase (1:3000 dilution), was added 100 µl/well, followed by incubation for 60 minutes at room temperature and subsequent washing and blotting. The substrate, freshly prepared 3,3’,5,5’-Tetramethylbenzidine (TMB), was added at 100 µl/well and incubated in the dark for 10 minutes. The enzyme-substrate reaction was stopped by adding 50 µl of 0.2 M H2SO4 to each well. Absorbance and antibody concentrations (mIU/ml) were estimated using the Mindray MR 96 A ELISA Microplate Reader (Shenzhen, P.R. China). Antibody responses were classified as suboptimal (< 10 mIU/ml) and optimal (≥ 10 mIU/ml). Statistical analysis Summary statistics were conducted with continuous data expressed as mean ± SD and categorical data expressed as frequencies and percentages. Stratified analysis of the participants’ characteristics were performed based on their hepatitis B antibody response levels. Comparative analyses were performed using the t-test for continuous variables and the chi-square or Fisher’s exact test for categorical variables. Graphs were generated to illustrate the relationship between participants’ characteristics and hepatitis B antibody responses. All analyses were conducted using GraphPad Prism version 6.07 and 10.1.1 (323). Multivariable logistic regression was employed to assess participants’ characteristics that predicted an optimal vaccination outcome (HBsAb ≥ 10 u/ml). Models were fitted with HBsAb vaccination status as the outcome and participants’ characteristics that are likely to biologically influence immunity levels as independent variables. Adjusted odds ratios with 95% confidence intervals were calculated for each independent variable. Results Demographic profile of healthcare workers vaccinated against HBV The study recruited 150 HBV-vaccinated healthcare professionals, achieving a participation rate of 97% and a response rate of 95%. Their characteristics across anthropometry, marital status and occupation are shown in Table 1. On average, the participants were 29.9 ± 6.94 years old, with comparable mean ages between males and females. Male subjects were significantly taller and heavier than their female counterparts, however, both groups had comparable BMIs. The mean systolic and diastolic blood pressures were 117.1 ± 12.8 mmHg and 76.81 ± 11.67 mmHg, respectively, with men recording higher systolic values than women. The study population comprised slightly more males (52.7%) than females (47.3%), and most of the participants were single (57.33%). Healthcare professionals were predominantly biomedical scientists (52.67%), followed by nurses (30.00%) and physicians (12.00%), as shown in Table 1. Table 1The demographic characteristics of the study population.VariablesTotal participants(n = 150)Males(n = 79)Females(n = 71)p - valueAge (yrs)29.90 ± 6.9430.63 ± 6.7729.08 ± 7.090.1733Weight (Kg)63.27 ± 9.4565.37 ± 9.4160.94 ± 8.990.0039Height (m)1.67 ± 0.061.70 ± 0.061.64 ± 0.06< 0.0001BMI22.65 ± 3.0022.74 ± 2.9922.56 ± 2.990.7123Systolic BP117.10 ± 12.84121.60 ± 12.61112.10 ± 11.21< 0.0001Diastolic BP76.81 ± 11.6777.80 ± 13.7175.72 ± 8.860.2775Marital statusSingle86(57.33)47(59.49)39(54.93)0.6369Married64(42.67)32(40.51)32(45.07)ProfessionBiomedical Scientist79(52.67)42(53.17)37(52.11)0.1589Physician18(12.00)10(12.66)8(11.28)Nurse45(30.00)20(25.32)25(35.21)Others8(5.33)7(8.86)1(1.41)Continuous data are presented as mean ± SD. Categorical data are presented as frequencies with percentages in parenthesis. BMI: body mass index; BP: blood pressure. Table 1The demographic characteristics of the study population.VariablesTotal participants(n = 150)Males(n = 79)Females(n = 71)p - valueAge (yrs)29.90 ± 6.9430.63 ± 6.7729.08 ± 7.090.1733Weight (Kg)63.27 ± 9.4565.37 ± 9.4160.94 ± 8.990.0039Height (m)1.67 ± 0.061.70 ± 0.061.64 ± 0.06< 0.0001BMI22.65 ± 3.0022.74 ± 2.9922.56 ± 2.990.7123Systolic BP117.10 ± 12.84121.60 ± 12.61112.10 ± 11.21< 0.0001Diastolic BP76.81 ± 11.6777.80 ± 13.7175.72 ± 8.860.2775Marital statusSingle86(57.33)47(59.49)39(54.93)0.6369Married64(42.67)32(40.51)32(45.07)ProfessionBiomedical Scientist79(52.67)42(53.17)37(52.11)0.1589Physician18(12.00)10(12.66)8(11.28)Nurse45(30.00)20(25.32)25(35.21)Others8(5.33)7(8.86)1(1.41)Continuous data are presented as mean ± SD. Categorical data are presented as frequencies with percentages in parenthesis. BMI: body mass index; BP: blood pressure. The demographic characteristics of the study population. Continuous data are presented as mean ± SD. Categorical data are presented as frequencies with percentages in parenthesis. BMI: body mass index; BP: blood pressure. General anti-HBs titer and HBsAg reactivity among vaccinated healthcare professionals To assess the immune response of HCW to hepatitis B vaccination, we analyzed serum samples for anti-HBs antibody titers and HBsAg reactivity. Overall, the mean anti-HBs antibody titer among the participants was 338.6 ± 387.6 mIU/ml (Table 2). Antibody titers were similar between males and females (p-value = 0.2817), although males (mean = 363.6 ± 391.0 mIU/ml) showed a slightly higher response than females (mean = 310.8 ± 384.5 mIU/ml). Participants with anti-HBs titers ≥ 10 mIU/ml, categorized as optimal responders, had a mean titer of 545.2 ± 360.2 mIU/ml (95%CI: 448.0–669.2.0.2). By contrast, suboptimal responders with titers < 10 mIU/ml demonstrated a mean titer of 1.6 ± 2.7 mIU/ml. Notably, one vaccinated HCW with a suboptimal anti-HBs antibody response tested positive for HBsAg, indicating a breakthrough infection, which represents 0.67% of the study population (Table 2). Table 2The anti-HBs titer and HBsAg reactivity among vaccinated healthcare professionals.Total (n = 150)Males (n = 79)Females (n = 71)p-valueAnti-HBs response (mIU/ml)Total338.6 ± 387.6363.6 ± 391.0310.8 ± 384.50.2817Suboptimal1.6 ± 2.71.7 ± 2.81.5 ± 2.70.5589Optimal545.2 ± 360.2541.1 ± 363.0550.6 ± 361.00.7152HBsAg statusNegative149(99.33)79(100.00)70(98.59)0.4733Positive1(0.67)0(0.00)1(1.41)Continuous data are presented as mean ± SD. Categorical data are presented as frequencies with percentages in parenthesis. HBsAg; hepatitis B surface antigen; Anti-HBs: hepatitis B antibody. suboptimal response, < 10 mIU/ml; optimal response, ≥ 10 m IU/ml. Table 2The anti-HBs titer and HBsAg reactivity among vaccinated healthcare professionals.Total (n = 150)Males (n = 79)Females (n = 71)p-valueAnti-HBs response (mIU/ml)Total338.6 ± 387.6363.6 ± 391.0310.8 ± 384.50.2817Suboptimal1.6 ± 2.71.7 ± 2.81.5 ± 2.70.5589Optimal545.2 ± 360.2541.1 ± 363.0550.6 ± 361.00.7152HBsAg statusNegative149(99.33)79(100.00)70(98.59)0.4733Positive1(0.67)0(0.00)1(1.41)Continuous data are presented as mean ± SD. Categorical data are presented as frequencies with percentages in parenthesis. HBsAg; hepatitis B surface antigen; Anti-HBs: hepatitis B antibody. suboptimal response, < 10 mIU/ml; optimal response, ≥ 10 m IU/ml. The anti-HBs titer and HBsAg reactivity among vaccinated healthcare professionals. Continuous data are presented as mean ± SD. Categorical data are presented as frequencies with percentages in parenthesis. HBsAg; hepatitis B surface antigen; Anti-HBs: hepatitis B antibody. suboptimal response, < 10 mIU/ml; optimal response, ≥ 10 m IU/ml. Factors influencing individuals’ response to hepatitis B vaccination To assess whether the response to hepatitis B vaccination was influenced by demographic factors and vaccination schedule, we analyzed the mean distribution of anti-HBs titers across age groups, sex, weight categories, and vaccination frequency and duration. Most participants were within the 20–29 age group, followed by 30–39 years, with the fewest in the 50–59 age group (Fig. 1). Age was not significantly associated with response to vaccination in the overall population or when stratified by sex (Fig. 1. A1 and A2). When anti-HBs antibody titers were compared across weight categories, the highest levels were observed in the underweight group, followed by the obese group, while the lowest levels occurred in the overweight group. There was however no significant association between weight categories and anti-HBs titers irrespective of sex (Fig. 1. B1 and B2). Interestingly, the number of vaccine doses received did not significantly influence anti-HBs antibody levels, with a similar trend observed when stratified by sex (Fig. 1. C1 and C2). In contrast, the duration since the last vaccination was strongly associated with anti-HBs titers. Participants vaccinated within the past year had mean titers approximately three-folds higher than those vaccinated earlier (1–3, 4–6, 7–9 and ≥ 10 years), as shown in Fig. 1D1. This suggests that anti-HBs antibody levels decline rapidly after the first-year post-vaccination. No sex-specific differences were noted in this decreasing trend (Fig. 1D2). Correlational analysis did not reveal significant associations between anti-HBs titers and either age or BMI, although titers declined slightly with age in males compared to females, and with BMI in females compared to males (Fig. 2). Although no statistically significant odds ratios were observed, female participant had 63% higher anti-HBs levels (OR 1.63; 95% CI: 0.79–3.37) compared to their male counterparts. Participants who exercised had 15% higher anti-HBs levels (OR 1.15; 95% CI: 0.55–2.38)compared to those who did not exercise. Conversely, one year increase in the time since last vaccination resulted in 4% decrease in anti-HBs titers (OR 0.96; 95% CI: 0.85–1.07)whilst one year increase in the age of participants was associated with a 3% decrease (OR 0.97; 95%CI: 0.92–1.02). A kg/m2 change in body mass index was associated with a 5% decrease in anti-HBs antibody levels (OR 0.95; 95% CI: 0.85–1.07) (Table 3). Anti-HBs seroprotection among vaccinated healthcare professionals We assessed anti-HBs seroprotection of the study population by estimating the proportion of participants with antibody titers ≥ 10 mIU/ml. Ninety-three (93) participants showed an optimal response to vaccination (≥ 10 mIU/ml), while the responses of the remaining 57 were suboptimal (< 10 mIU/ml), resulting in an overall seroprotection rate of 62.0% as shown in Table 4. No significant differences were observed between males and females, although seroprotection was slightly higher in males (35.33%) than females (26.67%) (Table 4). Likewise, there were no significant variations across age groups, BMI categories, professional groups, or vaccine dose frequencies. However, participants older than 40 years demonstrated significantly lower anti-HBs antibody levels compared to those aged 40 years or younger (Fig. 3). Notably, participants vaccinated within the past year, regardless of the number of doses received, all exhibited optimal responses, yielding a 100% seroprotection rate (Table 4; Fig. 4). Seroprotection declined over time since last vaccination, with the decline being more pronounced in males (Fig. 4). Among optimal responders, we further compared antibody titers between males and females across response categories (10–500, 501–1000, and > 1000 mIU/ml). Most participants were within the 501–1000 mIU/ml range comprising 17.33% males and 15.33% females (Table 5). Fig. 1The anti-HBs antibody levels among healthcare professionals stratified between age groups and gender (A1 - A2), weight category and gender (B1 - B2), vaccination frequency and gender (C1 - C2) and duration since last vaccination and gender (D1 - D2). Bar (__) represents the mean of the population under each category. The anti-HBs antibody levels among healthcare professionals stratified between age groups and gender (A1 - A2), weight category and gender (B1 - B2), vaccination frequency and gender (C1 - C2) and duration since last vaccination and gender (D1 - D2). Bar (__) represents the mean of the population under each category. Fig. 2Spearman correlation analysis showing association between; anti-HBs antibody titer and age (upper half) and BMI (lower half) in males, females, and total participants. Spearman correlation analysis showing association between; anti-HBs antibody titer and age (upper half) and BMI (lower half) in males, females, and total participants. Table 3Multivariable logistic regression analysis predicting anti-HBs optimal vaccination outcome (anti-HBs titer ≥ 10).VariableAOR (95% CI)Time since last vaccination (years)0.96 (0.85–1.07)Age (years)0.97 (0.92–1.02)Number of vaccines received11≥ 20.72 (0.23–2.21)ExerciseNo1Yes1.15 (0.55–2.38)BMI (kg/m2)0.95 (0.85–1.07)SexMale1Female1.63 (0.79–3.37)AOR = Adjusted Odds Ratio; CI = Confidence Interval. Table 3Multivariable logistic regression analysis predicting anti-HBs optimal vaccination outcome (anti-HBs titer ≥ 10).VariableAOR (95% CI)Time since last vaccination (years)0.96 (0.85–1.07)Age (years)0.97 (0.92–1.02)Number of vaccines received11≥ 20.72 (0.23–2.21)ExerciseNo1Yes1.15 (0.55–2.38)BMI (kg/m2)0.95 (0.85–1.07)SexMale1Female1.63 (0.79–3.37)AOR = Adjusted Odds Ratio; CI = Confidence Interval. Multivariable logistic regression analysis predicting anti-HBs optimal vaccination outcome (anti-HBs titer ≥ 10). AOR = Adjusted Odds Ratio; CI = Confidence Interval. Table 4The categorization of the anti-HBs antibody response and seroprotection among vaccinated healthcare professionals stratified according to individual characteristics.VariableSuboptimal response (< 10 mIU/ml)(n = 57)Optimal response(≥ 10 mIU/ml)(n = 93)p-valueGenderMale26(45.61)53(56.99)0.1831Female31(54.39)40(43.01)Age group (yrs)20–2930(52.63)60(64.52)0.361430–3919(33.33)24(25.81)40–497(12.28)6(6.45)50–591(1.75)3(3.23)BMIUnderweight1(1.75)4(4.30)0.3928Normal46(80.70)80(86.02)Overweight8(14.04)6(6.45)Obese2(3.51)3(3.23)ProfessionBMS33(57.90)47(50.54)0.8451Physician5(8.77)9(9.68)Nurse15(26.32)30(32.26)Others4(7.02)7(7.53)Dose frequencyOnce1(1.75)2(2.15)0.7320Twice4(7.02)10(10.75)Thrice52(91.23)81(87.10)Time since last vaccination (yrs)< 10(0.00)18(19.36)1–312(21.05)20(21.51)4–623(40.35)30(32.26)0.00287–915(26.32)22(23.66)≥ 107(12.28)3(3.23)Categorical data are presented as frequencies with percentages in parenthesis. Comparison between ranks of categorical data was performed using Fisher’s exact test. A p value of < 0.05 was considered significant. Table 4The categorization of the anti-HBs antibody response and seroprotection among vaccinated healthcare professionals stratified according to individual characteristics.VariableSuboptimal response (< 10 mIU/ml)(n = 57)Optimal response(≥ 10 mIU/ml)(n = 93)p-valueGenderMale26(45.61)53(56.99)0.1831Female31(54.39)40(43.01)Age group (yrs)20–2930(52.63)60(64.52)0.361430–3919(33.33)24(25.81)40–497(12.28)6(6.45)50–591(1.75)3(3.23)BMIUnderweight1(1.75)4(4.30)0.3928Normal46(80.70)80(86.02)Overweight8(14.04)6(6.45)Obese2(3.51)3(3.23)ProfessionBMS33(57.90)47(50.54)0.8451Physician5(8.77)9(9.68)Nurse15(26.32)30(32.26)Others4(7.02)7(7.53)Dose frequencyOnce1(1.75)2(2.15)0.7320Twice4(7.02)10(10.75)Thrice52(91.23)81(87.10)Time since last vaccination (yrs)< 10(0.00)18(19.36)1–312(21.05)20(21.51)4–623(40.35)30(32.26)0.00287–915(26.32)22(23.66)≥ 107(12.28)3(3.23)Categorical data are presented as frequencies with percentages in parenthesis. Comparison between ranks of categorical data was performed using Fisher’s exact test. A p value of < 0.05 was considered significant. The categorization of the anti-HBs antibody response and seroprotection among vaccinated healthcare professionals stratified according to individual characteristics. Categorical data are presented as frequencies with percentages in parenthesis. Comparison between ranks of categorical data was performed using Fisher’s exact test. A p value of < 0.05 was considered significant. Fig. 3The seroprotection levels between participants with maximum age of 40 years and those older. The continuous non-parametric distribution is shown as bar graph and error bar representing the mean and standard deviation respectively. Comparison between the means was performed employing Mann-Whitney test. The seroprotection levels between participants with maximum age of 40 years and those older. The continuous non-parametric distribution is shown as bar graph and error bar representing the mean and standard deviation respectively. Comparison between the means was performed employing Mann-Whitney test. Fig. 4Antibody response against HBV wanes with time among vaccinated subjects. The anti-HBs seroprotection among the total study subjects (A), males (B) and females (C). Chi-square Trend analysis was performed to compare groups. Antibody response against HBV wanes with time among vaccinated subjects. The anti-HBs seroprotection among the total study subjects (A), males (B) and females (C). Chi-square Trend analysis was performed to compare groups. Table 5Three tier categorizations of the anti-HBs antibody titer among optimal responders of vaccinated healthcare professionals stratified according to gender.Optimal response grade (mIU/ml)Males(n = 53)Females(n = 40)p - value10–50023(43.40)16(40.00)501–100026(49.10)23(57.50)0.4840> 10004(7.55)1(2.50)Categorical data are presented as frequencies with percentages in parenthesis. Comparison between ranks of categorical data was performed using Fisher’s exact test. A p value of < 0.05 was considered significant. Table 5Three tier categorizations of the anti-HBs antibody titer among optimal responders of vaccinated healthcare professionals stratified according to gender.Optimal response grade (mIU/ml)Males(n = 53)Females(n = 40)p - value10–50023(43.40)16(40.00)501–100026(49.10)23(57.50)0.4840> 10004(7.55)1(2.50)Categorical data are presented as frequencies with percentages in parenthesis. Comparison between ranks of categorical data was performed using Fisher’s exact test. A p value of < 0.05 was considered significant. Three tier categorizations of the anti-HBs antibody titer among optimal responders of vaccinated healthcare professionals stratified according to gender. Categorical data are presented as frequencies with percentages in parenthesis. Comparison between ranks of categorical data was performed using Fisher’s exact test. A p value of < 0.05 was considered significant. Discussion The study evaluated the hepatitis B antibody response among a vaccinated group of Ghanaian healthcare professionals. Overall, 62% of participants achieved optimal seroprotection, with more than half showing antibody levels between 501 and 1000 mIU/ml. Nevertheless, a substantial proportion of vaccinated individuals did not reach the threshold for protective antibody levels, indicating variability in the immune response within this cohort. Although vaccines are developed to offer protection, breakthrough infections have been documented, including among hepatitis B vaccinated individuals21,26,27. In the current study, we observed a breakthrough infection of less than 1%, and exclusively among participants with suboptimal antibody responses, suggesting that inadequate antibody levels can permit infection28. Our findings align with those of Obeng et al.21, which reported a 58% seroprotection rate and 2.4% breakthrough infection among vaccinated HCW in the Ashanti region. Similarly, a study among vaccinated HCW in the Cape Coast Metropolis documented a 91.8% seroprotection rate and a hepatitis B prevalence of 1%20. While our study observed a lower breakthrough infection rate, likely due to the smaller sample size, both studies highlight the persistence of suboptimal immunity despite full vaccination, reinforcing the need for post-vaccination antibody monitoring and identification of suboptimal responders among healthcare professionals in Ghana. Discrepancies in seroprotection rates may be explained by the timing of antibody testing, where antibody levels are known to peak 1–2 months after the final vaccine dose22,23, and testing outside this window, as was the case in our study, may underestimate the peak antibody responses. From a practical perspective, our findings highlight that a significant proportion of HCW remain at risk of HBV infection despite receiving the vaccine, primarily due to the absence of routine antibody titer monitoring in Ghana. Suboptimal immunity may arise from host-related factors, vaccine properties, handling, administration, or pathogen virulence29,30. Demographic and clinical variables such as age, sex, BMI classification and vaccination frequency were not associated with antibody response when stratified into optimal and suboptimal groups. However, males, younger participants and those who received repeated vaccine doses tended to mount stronger responses. Consistent with earlier reports28,31, participants aged 40 years and above demonstrated lower antibody titers compared with younger individuals. Furthermore, antibody levels were elevated among those vaccinated within the past year than among those vaccinated earlier, suggesting waning immunity over time. This decline is consistent with the established immunological principle that antibody titers peak within weeks following antigen exposure and subsequently diminish gradually29,32. Healthcare professionals are often exposed to the hazard of needle-stick injuries in the course of their duties, with an estimated 5.9% exposed annually to blood-borne HBV infections globally33,34. Robust immunity is therefore crucial to minimize vulnerability following accidental exposure. In our study, nearly 40% of HCW who may have initially demonstrated robust immune responses were at risk of reduced seroprotection between 1 and 3 years after vaccination. This underscores the potential value of adhering to post vaccination recommendations as set by WHO and CDC23,24 to identify HCWs who may not have developed the requisite amount of the antibodies needed to confer protection after the primary vaccination. Such individuals may benefit from revaccination. Approximately 5–10% of healthy adults fail to mount adequate responses to hepatitis B vaccination35, highlighting the need to identify healthcare providers who remain unprotected. Current WHO and CDC guidelines23,24 recommend that all HCW should undergo post-vaccination serological testing for anti-HBs antibody titers 1–2 months after completing the vaccination to confirm adequate immune response (≥ 10 mIU/ml). This is critical for identifying individuals who fail to achieve protective antibody levels after two complete vaccination series (nonresponders) and for counseling them appropriately given their susceptibility. Although our study included all vaccinated HCW irrespective of the time since their last vaccination and did not specifically identify true nonresponders, it highlighted a 100% seroprotection rate among those vaccinated within one year. This finding contrasts with the report by Senoo-Dogbey and colleagues13, who observed a seroprotection rate of 91.3% among HCW from five selected hospitals in Accra, six months postvaccination. The discrepancy may be attributable to differences in study design or sample size, underscoring the need for larger, standardized evaluations to better characterize seroprotection rates among Ghanaian healthcare workers. While hepatitis B vaccination confers substantial protection among HCW in Ghana, a considerable proportion fail to achieve optimal antibody titers over time. Seroprotection was highest among participants within one year of vaccination, suggesting waning immunity in subsequent years and underscoring the importance of timing in post-vaccination evaluation. Although true nonresponders were not explicitly identified, the presence of breakthrough infection among suboptimal responders emphasizes the vulnerability of this group. Taken together, these findings call for the integration of routine post-vaccination antibody testing into occupational health protocols in Ghana. Strengthening such measures is essential to safeguard HCW against occupational HBV exposure and to align national practices with international recommendations. It is recommended that management of healthcare centers should implement policies to screen and vaccinate all categories of HCW at the time of recruitment, followed by post vaccination measurement of antibody titers, which will be cost effective compared to post-exposure prophylaxis with immunoglobulins. Study limitations Whilst the study has important findings, there are notable limitations. First, the cross-sectional design limits the ability to infer the dynamics of antibody persistence over time. Secondly, post-vaccination serological testing was not conducted within the recommended 1–2 months following vaccine completion when antibody titers peak, this may have affected the identification of true nonresponders. Additionally, the study did not include testing for anti-HBc, which would have distinguished immunity from natural infection from vaccine-induced protection. Finally, the sample size, while adequate for descriptive analysis, may have limited the statistical power to detect smaller associations with demographic or clinical factors. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1